BR112018070161A2 - moduladores de receptores de estrogênio - Google Patents

moduladores de receptores de estrogênio

Info

Publication number
BR112018070161A2
BR112018070161A2 BR112018070161-0A BR112018070161A BR112018070161A2 BR 112018070161 A2 BR112018070161 A2 BR 112018070161A2 BR 112018070161 A BR112018070161 A BR 112018070161A BR 112018070161 A2 BR112018070161 A2 BR 112018070161A2
Authority
BR
Brazil
Prior art keywords
estrogen receptor
receptor modulators
compounds
formula
receptor alpha
Prior art date
Application number
BR112018070161-0A
Other languages
English (en)
Inventor
Qinhua Huang Peter
Helen Slee Deborah
Gajanan Hegde Sayee
Daniel Hopkins Chad
Duane Bunker Kevin
Robert Pinchman Joseph
Kumar Sit Rakesh
Original Assignee
Zeno Royalties & Milestones, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones, LLC filed Critical Zeno Royalties & Milestones, LLC
Publication of BR112018070161A2 publication Critical patent/BR112018070161A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
    • C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

os compostos de fórmula (i) são moduladores alfa do receptor de estrogênio, em que as variáveis na fórmula (i) são descritas na divulgação. tais compostos, assim como seus sais e composições farmaceuticamente aceitáveis, são úteis para o tratamento de doenças ou condições que são dependentes do receptor de estrogênio alfa e/ou mediadas pelo receptor de estrogênio alfa, incluindo condições caracterizadas por proliferação celular excessiva, tal como o câncer de mama.
BR112018070161-0A 2016-04-01 2017-03-29 moduladores de receptores de estrogênio BR112018070161A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317254P 2016-04-01 2016-04-01
US62/317,254 2016-04-01
PCT/US2017/024809 WO2017172957A1 (en) 2016-04-01 2017-03-29 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
BR112018070161A2 true BR112018070161A2 (pt) 2019-02-12

Family

ID=59966438

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070161-0A BR112018070161A2 (pt) 2016-04-01 2017-03-29 moduladores de receptores de estrogênio

Country Status (15)

Country Link
US (5) US20190142811A1 (pt)
EP (1) EP3442971A4 (pt)
JP (2) JP6926189B2 (pt)
KR (2) KR102401841B1 (pt)
CN (4) CN113717170A (pt)
AR (1) AR108011A1 (pt)
AU (3) AU2017242027B2 (pt)
BR (1) BR112018070161A2 (pt)
CA (1) CA3017388C (pt)
IL (3) IL295050A (pt)
MX (2) MX2018011419A (pt)
RU (1) RU2738646C2 (pt)
SG (1) SG11201807708SA (pt)
TW (2) TWI746535B (pt)
WO (1) WO2017172957A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2842579T3 (es) 2016-02-05 2021-07-14 Inventisbio Llc Degradadores de los receptores de estrógenos selectivos y sus usos
SG11201807708SA (en) 2016-04-01 2018-10-30 Zeno Royalties & Milestones Llc Estrogen receptor modulators
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
IL272875B2 (en) 2017-09-11 2023-10-01 Recurium Ip Holdings Llc Continuous flow processes for the preparation of bicyclic compounds
EP3709997A1 (en) * 2017-11-16 2020-09-23 Novartis AG Pharmaceutical combination comprising lsz102 and ribociclib
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
EP3993787A4 (en) * 2019-08-06 2023-07-12 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS
US20220389006A1 (en) * 2019-11-04 2022-12-08 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
MX2022007628A (es) * 2019-12-20 2022-08-25 Recurium Ip Holdings Llc Combinaciones.
WO2021127046A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
WO2021127042A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
AU2020407572A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
KR20220119418A (ko) * 2019-12-20 2022-08-29 리커리엄 아이피 홀딩스, 엘엘씨 조합물
AU2021259583A1 (en) * 2020-04-22 2022-11-24 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
AU2021343525A1 (en) * 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
IL309986A (en) * 2021-07-08 2024-03-01 Olema Pharmaceuticals Inc Methods for treating diseases related to estrogen receptors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024200A1 (en) 1994-03-11 1995-09-14 Eli Lilly And Company Method for treating 5ht2b receptor related conditions
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
TWI671297B (zh) * 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
CA2767083C (en) * 2009-07-28 2017-05-16 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
US8754099B2 (en) 2010-01-15 2014-06-17 Merck Sharp & Dohme Corp Oxadiazole beta carboline derivatives as antidiabetic compounds
EP2534152B1 (en) * 2010-02-11 2018-05-02 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US20130172320A1 (en) 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9029574B2 (en) * 2011-01-27 2015-05-12 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
CN102432608B (zh) 2011-11-01 2013-04-17 浙江大学 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EA027533B1 (ru) * 2011-12-31 2017-08-31 Бейджен, Лтд. Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
TR201806882T4 (tr) 2013-02-19 2018-06-21 Novartis Ag Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri.
US9586952B2 (en) 2013-03-14 2017-03-07 Genentech, Inc. Polycyclic estrogen receptor modulators and uses thereof
EP3360875A1 (en) 2013-05-28 2018-08-15 Astrazeneca AB Chemical compounds
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CN104693211A (zh) 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
TW201613891A (en) * 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
EP3143007B1 (en) 2014-05-16 2018-07-11 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
USRE49128E1 (en) 2014-10-09 2022-07-12 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof
CA2983403A1 (en) 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN107406457B (zh) * 2015-06-16 2019-02-01 江苏恒瑞医药股份有限公司 哌啶类衍生物、其制备方法及其在医药上的应用
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
ES2842579T3 (es) * 2016-02-05 2021-07-14 Inventisbio Llc Degradadores de los receptores de estrógenos selectivos y sus usos
SG11201807708SA (en) 2016-04-01 2018-10-30 Zeno Royalties & Milestones Llc Estrogen receptor modulators
CN109310664A (zh) 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
WO2018001232A1 (zh) * 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
JP7050770B2 (ja) * 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Also Published As

Publication number Publication date
CA3017388A1 (en) 2017-10-05
AU2020294196B2 (en) 2022-06-16
TW201736334A (zh) 2017-10-16
AU2017242027A1 (en) 2018-10-11
KR20190002478A (ko) 2019-01-08
US11065233B2 (en) 2021-07-20
IL295050A (en) 2022-09-01
US20200261428A1 (en) 2020-08-20
AU2022204025A1 (en) 2022-06-30
TWI746535B (zh) 2021-11-21
JP6926189B2 (ja) 2021-08-25
MX2018011419A (es) 2019-06-06
CA3017388C (en) 2024-03-12
CN112679495A (zh) 2021-04-20
CN109311870A (zh) 2019-02-05
IL261654A (en) 2018-10-31
RU2018132037A3 (pt) 2020-05-15
EP3442971A4 (en) 2020-01-01
IL285318B (en) 2022-09-01
JP2019515026A (ja) 2019-06-06
RU2018132037A (ru) 2020-05-12
KR20220071293A (ko) 2022-05-31
AU2017242027B2 (en) 2020-10-08
CN112745316A (zh) 2021-05-04
US10959989B2 (en) 2021-03-30
JP2021176911A (ja) 2021-11-11
US20210330651A1 (en) 2021-10-28
US20200261430A1 (en) 2020-08-20
EP3442971A1 (en) 2019-02-20
CN109311870B (zh) 2021-09-21
WO2017172957A1 (en) 2017-10-05
RU2738646C2 (ru) 2020-12-15
SG11201807708SA (en) 2018-10-30
AR108011A1 (es) 2018-07-04
CN113717170A (zh) 2021-11-30
IL261654B (en) 2021-08-31
TW202235418A (zh) 2022-09-16
CN112679495B (zh) 2023-03-28
MX2022005780A (es) 2022-06-09
IL285318A (en) 2021-09-30
US11065234B2 (en) 2021-07-20
KR102401841B1 (ko) 2022-05-25
US20200261429A1 (en) 2020-08-20
AU2020294196A1 (en) 2021-01-28
US20190142811A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
BR112018070161A2 (pt) moduladores de receptores de estrogênio
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112017006464A2 (pt) bloqueio de cd73
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112018075284A2 (pt) derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
CO2018007738A2 (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
BR112018075166A2 (pt) derivados de carbonucleosídeo substituídos úteis como agentes anticâncer
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
BR112018075939A2 (pt) compostos heterocíclicos como antibacterianos
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: RECURIUM IP HOLDINGS, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]